Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Pavinetant (Primary)
- Indications Hot flashes
- Focus Proof of concept; Therapeutic Use
- 08 Nov 2017 Status changed from active, no longer recruiting to discontinued, as reported in a Millendo Therapeutics media release.
- 15 May 2017 According to a Millendo Therapeutics media release, data from this study will be presented at the 19th European Congress of Endocrinology (ECE).
- 03 Apr 2017 Results published in a Millendo Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History